Zealand Pharma Extraordinary General Meeting May 26: Camilla Sylvest Elected to Board of Directors; Petrelintide and Survodutide Programs Anchor 2026 Pipeline
Zealand Pharma A/S held its Extraordinary General Meeting at Plesner Advokatpartnerselskab in Copenhagen on May 26, 2026. All proposals presented were approved, with Camilla Sylvest elected to the Board of Directors as recommended by the Nomination Committee. No other shareholder-elected board composition changes were proposed. Zealand's 2026 pipeline anchors on three programs: petrelintide (ZP8396, amylin analog under a $5.3B March 2026 Roche partnership), survodutide (BI 456906, dual GLP-1/glucagon agonist partnered with Boehringer Ingelheim, SYNCHRONIZE-1 obesity Phase 3 readout April 2026 documenting 16.6% weight loss), and the next-generation amylin and glucagon programs. The corporate-governance update is routine; the strategic story remains the SYNCHRONIZE-MASH Phase 3 readout expected late 2026, which positions survodutide as a leading candidate for the dual GLP-1/glucagon agonist class in MASH alongside pemvidutide.